Sopharma Trading ADXBUL:SFT -0.69%83 Altman Z-Score is 3.08 as of Jul. 13, 2026, which is 0% below its 10-year median of 3.09. GuruFocus rates XBUL:SFT with a GF Score™ of 83/100 and a GF Value™ of €7.66 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 117 Medical Distribution companies, Sopharma Trading AD ranks better than 64.1% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Good Sign:
Altman Z-score of 3.08 is strong.
Sopharma Trading AD has a Altman Z-Score of 3.08, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for Sopharma Trading AD's Altman Z-Score or its related term are showing as below:
XBUL:SFT'
s Altman Z-Score Range Over the Past 10 Years
Min: 2.35 Med: 3.09 Max: 3.63
Current: 3.08
During the past 13 years, Sopharma Trading AD's highest Altman Z-Score was 3.63. The lowest was 2.35. And the median was 3.09.
Sopharma Trading AD (XBUL:SFT) Altman Z-Score Explanation
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
Altman Z-Score does not apply to financial companies.
Sopharma Trading AD Altman Z-Score Related Terms
Sopharma Trading AD Altman Z-Score Historical Data
* Premium members only.
The historical data trend for Sopharma Trading AD's Altman Z-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XBUL:SFT vs MCK, CAH, COR: Altman Z-Score Comparison
For the Medical Distribution subindustry, Sopharma Trading AD's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sopharma Trading AD Altman Z-Score vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sopharma Trading AD's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where Sopharma Trading AD's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
Sopharma Trading AD's Altman Z-Score for today is calculated with this formula:
Z
=
1.2
*
X1
+
1.4
*
X2
+
3.3
*
X3
+
0.6
*
X4
+
1.0
*
X5
=
1.2
*
0.1532
+
1.4
*
0.0307
+
3.3
*
0.078
+
0.6
*
0.2714
+
1.0
*
2.4343
=
3.08
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
Sopharma Trading AD (XBUL:SFT) has a Altman Z-Score of 3.08 as of Jul. 13, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on Sopharma Trading AD and its competitors. This is near median its historical median of 3.09. Over the past decade, Sopharma Trading AD's Altman Z-Score has ranged from 2.35 to 3.63. According to the industry distribution chart, Sopharma Trading AD ranks #42 out of 117 companies in the Medical Distribution industry, placing it in the top 35.9%.
Is Sopharma Trading AD's Altman Z-Score too high?
Sopharma Trading AD's current Altman Z-Score of 3.08 is near median its 10-year median of 3.09. Over the past 10 years, this metric has ranged from a low of 2.35 to a high of 3.63. The Medical Distribution industry median Altman Z-Score is 2.57. Sopharma Trading AD's value of 3.08 is 19.8% above this industry median. Based on the distribution chart, Sopharma Trading AD ranks #42 out of 117 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Sopharma Trading AD has a GF Score™ of 83/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sopharma Trading AD's Altman Z-Score compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Sopharma Trading AD ranks #42 out of 117 companies for Altman Z-Score. This puts Sopharma Trading AD in the upper half of its industry. The industry median Altman Z-Score is 2.57. Sopharma Trading AD's value of 3.08 is 19.8% above this benchmark. Historically, Sopharma Trading AD's own Altman Z-Score has ranged from 2.35 to 3.63 over the past decade. While the company's 10-year median is 3.09 vs. the industry median of 2.57, Sopharma Trading AD has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Medical Distribution company?
The median Altman Z-Score among Medical Distribution companies is 2.57, based on 117 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sopharma Trading AD's current Altman Z-Score of 3.08 is 19.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on Sopharma Trading AD and its competitors. For the Medical Distribution industry, the median Altman Z-Score is 2.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sopharma Trading AD's current Altman Z-Score is 3.08, which is near median its own 10-year median of 3.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sopharma Trading AD stock overvalued right now?
Based on GuruFocus' analysis, Sopharma Trading AD (XBUL:SFT) is currently considered Significantly Undervalued. The stock's GF Value™ is €7.66, compared to a current price of €2.86 — trading 62.7% below its estimated fair value. The current Altman Z-Score is 3.08, which is near median its 10-year median of 3.09 and 19.8% above the Medical Distribution industry median of 2.57. Sopharma Trading AD's overall GF Score™ is 83/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For Sopharma Trading AD (XBUL:SFT), the current Altman Z-Score is 3.08 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sopharma Trading AD (XBUL:SFT) Overvalued in 2026?
Based on GuruFocus' analysis, Sopharma Trading AD stock appears to be undervalued.
The current stock price of €2.86 is trading 62.7% below its estimated GF Value™ of €7.66.
GuruFocus considers Sopharma Trading AD to be Significantly Undervalued.
Key valuation signals for XBUL:SFT:
Altman Z-Score: 3.08 (near median its 10-year median of 3.09)
GF Value™: €7.66 vs. price of €2.86 (62.7% below fair value)
Industry Position: 19.8% above the Medical Distribution median (#42 of 117)
No single metric tells the full story. See the XBUL:SFT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sopharma Trading AD is a Bulgaria based company operating in the pharmaceutical sector. The company is engaged in the distribution of pharmaceutical items, including a portfolio of international brands, medicinal products, medical supplies, sanitary and hygienic materials, vitamins, nutritional supplements, cosmetics, medical equipment, and equipment. It also provides turnkey solutions for the construction of medical and hospital establishments. In addition, the group also caters logistics solutions for import, storage, and distribution of goods to end customers.
83GF Score
Get the complete analysis for XBUL:SFT
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XBUL:SFT has been successfully added to your 
